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 Biomarkers are needed to improve Lewy body dementia (LBD) diagnosis and measure treatment
response.
 There is substantial heterogeneity in neurophysiology biomarker methodologies limiting comparison.
 However, there is tentative evidence to suggest neurophysiological approaches may show promise as
potential biomarkers of LBD.
a b s t r a c t
Objective: Lewy body dementias (LBD) include both dementia with Lewy bodies (DLB) and Parkinson’s
disease with dementia (PDD), and the differentiation of LBD from other neurodegenerative dementias
can be difﬁcult. Currently, there are few biomarkers which might assist early diagnosis, map onto LBD
symptom severity, and provide metrics of treatment response. Traditionally, biomarkers in LBD have
focussed on neuroimaging modalities; however, as biomarkers need to be simple, inexpensive and
non-invasive, neurophysiological approaches might also be useful as LBD biomarkers.
Methods: In this review, we searched PubMED and PsycINFO databases in a semi-systematic manner in
order to identify potential neurophysiological biomarkers in the LBDs.
Results: We identiﬁed 1491 studies; of these, 37 studies speciﬁcally examined neurophysiological
biomarkers in LBD patients. We found that there was substantial heterogeneity with respect to
methodologies and patient cohorts.
Conclusion: Generally, many of the ﬁndings have yet to be replicated, although preliminary ﬁndings rein-
force the potential utility of approaches such as quantitative electroencephalography and motor cortical
stimulation paradigms.
Signiﬁcance: Various neurophysiological techniques have the potential to be useful biomarkers in the
LBDs. We recommend that future studies focus on maximising the diagnostic speciﬁcity and sensitivity
of the most promising neurophysiological biomarkers.
 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Dementia with Lewy bodies (DLB) is the second most common
cause of degenerative dementia in older people after Alzheimer’sdisease (AD), where approximately 10–15% of dementia cases
demonstrate Lewy body pathology at autopsy (McKeith, 2006). In
Parkinson’s disease (PD), dementia is a common outcome and up
to 80% of PD patients eventually develop dementia as the disease
progresses (Aarsland et al., 2003; Hely et al., 2008). Collectively,
DLB and Parkinson’s disease dementia (PDD) can be grouped under
the umbrella term of Lewy body dementias (LBD) due to the over-
lap in symptom proﬁle, similar treatment response, and common
underlying neuropathology of alpha-synuclein aggregation
(Francis, 2009). Individuals with LBD therefore represent an
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sponding impact upon health and society.
Cognitively, LBD patients display marked deﬁcits in executive
and visuo-spatial/visuo-perceptual function, and variations in their
levels of arousal and attention; the latter are typically referred to
as ‘cognitive ﬂuctuations’ (Lee et al., 2012; McKeith et al., 2005;
Mollenhauer et al., 2010; Mosimann et al., 2004). Additional clini-
cal features include spontaneous Parkinsonism motor features
(McKeith et al., 2005), but non-motor manifestations such as visual
hallucinations, autonomic dysfunction, syncope, repeated falls,
rapid eye movement sleep behaviour disorder (RBD), delusions
and depression are also typical in the LBDs and can cause signiﬁ-
cant difﬁculties for patients (McKeith et al., 2005).
There are a number of treatment challenges in the LBDs.
Profound cholinergic deﬁcits occur in LBD, and are even more
apparent than those observed in AD (Samuel et al., 2000). The
remediation of cholinergic function, by the use of cholinesterase
inhibitors such as donepezil, rivastigmine and galantamine, may
have cognitive and neuropsychiatric beneﬁts, including improve-
ments in global cognitive function, attentional function and
activities of daily living (McKeith et al., 2004). However,
intra-individual variations are frequently observed in the response
to these treatments (Burn and McKeith, 2003) and responder strat-
iﬁcation, through the use of apposite biomarkers, would aid the
clinical management of LBD. Beyond the cholinesterase inhibitors,
there are few efﬁcacious pharmacological treatment options, and
agents such as memantine have been tried with mixed success
(Aarsland et al., 2009; Emre et al., 2010; Matsunaga et al., 2015).
Consequently, there is now a great deal of interest in the search
for viable and speciﬁc biomarkers in LBD, as these would assist
the development of novel therapeutics and provide an accurate
method for monitoring treatment response.
Existing candidate biomarkers, which have been used in the
LBDs, have included clinical, biochemical, genetic, and neuroimag-
ing markers, such as alpha-synuclein or amyloid beta levels within
cerebrospinal ﬂuid (CSF), or alpha-synuclein gene mutations
(Hanagasi et al., 2013; Lippa et al., 2007). Generally, the utility of
these candidate biomarkers has only been supported in a research
context, aside from dopamine transporter imaging, which due to
its high speciﬁcity in differentiating DLB from AD (McKeith et al.,
2007) is now recommended clinically as a method for conﬁrming
the diagnosis of DLB in uncertain cases (Mak et al., 2014).
However, dopamine transport imaging remains expensive, exposes
an individual to radioactivity and provides little or no information
regarding the disease progression or prognosis. Additionally, this
method does not overtly correlate with the severity of cognitive
or neuropsychiatric symptoms in DLB. Similarly whilst magnetic
resonance imaging (MRI) has been shown to be a useful tool in
the differential diagnosis of the dementias (Mak et al., 2014) its
use in LBD is relatively limited and compared to other imaging
modalities, MRI has the disadvantage of being relatively high in
cost. Alternatively, cerebrospinal ﬂuid (CSF) examination has also
been mooted as a potential biomarker in LBD, where one potential
application might include the assessment of alpha-synuclein levels
(Mukaetova-Ladinska et al., 2010). However, the clinical utility of
this approach remains uncertain, and further methodological
developments are required prior to routine use (Lim et al., 2013).
A further disadvantage of the use of CSF as a biomarker is that it
cannot be collected in a non-invasive manner.
In summary, there is a clear and pressing need to identify useful
biomarkers of LBD in order to: (1) expedite the early diagnosis of
LBD and enable differential diagnosis to be obtained, particularly
during the prodromal phase of the disease; (2) improve our under-
standing of LBD progression; (3) provide a means to accurately
monitor the therapeutic response to treatment; and (4) ultimately
develop early disease-modifying interventions. One modalitywhich has not been extensively examined in LBD is the use of neu-
rophysiological approaches, despite their increasing relevance in
AD (de Waal et al., 2011; van Straaten et al., 2014). As biomarkers
should ideally be non-invasive, inexpensive, simple to use and
technically validated (Gerlach et al., 2012), in this regard, a variety
of neurophysiological techniques, and in particular electroen-
cephalography (EEG), may be useful biomarkers of LBD.
In the present review we therefore sought to explore the rele-
vant literature in order to identify the way in which neurophysio-
logical approaches have been applied in LBD. Speciﬁcally, we
sought to evaluate their diagnostic utility, assess whether these
markers map onto symptomatic phenotypes, and ﬁnally, examine
their performance as potential markers of treatment response.2. Method
2.1. Search methods and inclusion/exclusion criteria
In order to identify the available literature regarding current
and potential neurophysiological biomarkers in LBD, PubMED
(until 29 April 2015) and PsycINFO (from 1967 until April Week
3 2015) databases were searched independently by two of the
authors (RAC & GJE) using the following terms: ‘‘Lewy⁄’’,
‘‘Parkinson’s disease with dementia’’, ‘‘Parkinson’s disease with
mild cognitive impairment’’, ‘‘dementia with Lewy⁄’’ AND ‘‘bereit
schaftspotential’’, ‘‘biomarker’’, ‘‘blink recovery’’, ‘‘blink reﬂex’’,
‘‘contingent negative variation’’, ‘‘cortical silent periods’’, ‘‘EEG’’, ‘‘
electroencephalography’’, ‘‘electrophysiology’’, ‘‘ERP’’,
‘‘event-related potential’’, ‘‘evoked potential’’, ‘‘ﬂicker fusion’’,
‘‘ﬂutter fusion’’ ‘‘H-reﬂex’’, ‘‘induced potential’’, ‘‘intra-cortical
facilitation’’, ‘‘ipsilateral silent periods’’, ‘‘LDAEP’’, ‘‘long-interval
intracortical inhibition’’, ‘‘long-latency stretch reﬂex’’, ‘‘magnetoen
cephalography’’, ‘‘MEG’’, ‘‘mismatch negativity’’, ‘‘motor evoked
potential’’, ‘‘nerve stimulation’’, ‘‘neurophysiology’’, ‘‘prepulse
inhibition’’, ‘‘SAI’’, ‘‘short afferent inhibition’’, ‘‘short-interval intra-
cortical inhibition’’, ‘‘startle’’, ‘‘sympathetic skin response’’, ‘‘TMS’’
and ‘‘transcranial magnetic stimulation’’.
Studies which focussed only on the clinical phenotype of LBD,
those which focussed on the behavioural aspects of LBD, or studies
which employed exclusively neuroimaging techniques, were
excluded. This search strategy (Fig. 1) resulted in a total of 1491
potential articles. Article titles and abstracts were screened for rel-
evance, and the reference sections of included papers were
searched in order to identify any additional studies. Review,
non-English and duplicate articles were removed.
For an article to be included, LBD participants were required to
have met established diagnostic criteria for either probable DLB or
PDD (Emre et al., 2007; McKeith et al., 2005), or, for PDD studies
published prior to the 2007 criteria, on the basis of the fourth edi-
tion of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) (American Psychiatric Association, 1994), or LBD partici-
pants who had neuropathological post-mortem conﬁrmation of
their diagnosis, in accordance with previously-published guideli-
nes (Fujishiro et al., 2008; McKeith et al., 2005). This resulted in
a ﬁnal total of 37 studies.3. Results
The most common modality used was EEG, as a total of 24 EEG
studies were identiﬁed (see Supplementary Table S1 for details);
15 of which predominantly examined resting-state EEG and 6 of
which examined event-related potentials (ERPs). A total of 12 stud-
ies employed a range of other neurophysiological techniques (see
Supplementary Table S2) including TMS (5 studies), MEG (2 stud-
ies), and the assessment of the blink reﬂex (2 studies). Studies
Search terms: 
“Lewy*”, “Parkinson’s disease with dementia”, “Parkinson’s disease with mild cognitive 
impairment”, “dementia with Lewy*” 
AND 
“bereitschaftspotential”, “biomarker”, “blink recovery”, “blink reflex”, “contingent 
negative variation”, “cortical silent periods”, “EEG”, “electroencephalography”, 
“electrophysiology”, “ERP”, “event-related potential”, “evoked potential”, “flicker 
fusion”, “flutter fusion” “H-reflex”, “induced potential”, “intra-cortical facilitation”, 
“ipsilateral silent periods”,  “LDAEP”, “long-interval intracortical inhibition”, “long-
latency stretch reflex”,  “magnetoencephalography”, “MEG”, “mismatch negativity”, 
“motor evoked potential”, “nerve stimulation”, “neurophysiology”, “prepulse inhibition”, 
“SAI”, “short afferent inhibition”, “short-interval intracortical inhibition”, “startle”, 
“sympathetic skin response”, “TMS” and “transcranial magnetic stimulation”. 
PubMED 
(Until 29 April 2015) 
PsycINFO 
(From 1967 Until April 
Week 4 2015) 
1,114 articles for 
potential inclusion 
377 articles for potential 
inclusion 
69 articles for inclusion 131 articles for inclusion 
Articles screened: 
(Removal of studies which focussed on clinical phenotype of LBD, behavioural 
aspects or neuroimaging, review articles and non-English articles) 
200 articles for inclusion 
Removal of duplicate 
articles 
37 articles for inclusion: 
EEG: 24 studies 
Other techniques: 13 studies 
Fig. 1. Search strategy and selection criteria.
Table 1
Potential neurophysiological biomarkers in the Lewy body dementias.
Neurophysiological
biomarker
Presumed functional
signiﬁcance in LBD
Example references
Autonomic measures:
(cardiovascular
function, heart rate
variability,
sympathetic sweat
response, skin
vasomotor reﬂex and
sympathetic skin
response)
Autonomic dysfunction is
common and often an
early symptom of LBD.
Therefore, measures
which detect autonomic
system dysfunction
might aid the early
detection of LBD
Akaogi et al. (2009)
and Negami et al.
(2013)
Blink reﬂex As brainstem
neuropathology has been
proposed to be a feature
of early LBD, an abnormal
blink reﬂex may indicate
the development of LBD
Anzellotti et al.
(2008) and Bonanni
et al. (2007)
EEG: resting-
state/coherence
analysis
Resting-state EEG
analytic methods (e.g.
through the comparison
of power spectra between
groups) can assess
underlying cortical
activity, potentially
providing an insight into
neurotransmitter (e.g.
cholinergic) deﬁcits in
LBD. Coherence analysis
may allow the
assessment of functional
connectivity in the LBDs
EEG: event-related
potentials (visual or
auditory)
Task-dependent event-
related potential studies
may allow the
investigation of
attentional and cognitive
deﬁcits in LBD
Kurita et al. (2010),
Perriol et al. (2005)
and Pugnetti et al.
(2010)
MEG MEG measures the same
source signal as EEG, can
measure oscillatory
cortical function, and
might be a measure of
cholinergic deﬁcits in LBD
Bosboom et al.
(2009) and
Franciotti et al.
(2006)
TMS (SAI) SAI is a tool which can be
used to examine the
cholinergic deﬁcit in LBD
Celebi et al. (2012)
and Di Lazzaro et al.
(2007)
Abbreviations: EEG: electroencephalography; LBD: Lewy body dementia; MEG:
magnetoencephalography; SAI: short afferent inhibition; TMS: transcranial mag-
netic stimulation.
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heart rate variability (2 studies), and one study which assessed
the auditory startle reaction were also considered. Due to the
heterogeneity of studies and the wide range of neurophysiological
approaches, these data were not amenable to meta-analysis.
Therefore, only narrative descriptions of these studies are pro-
vided. An overview of the neurophysiological biomarkers exam-
ined and their presumed functional signiﬁcance in LBD are
included in Table 1.4. Discussion
4.1. Electroencephalography
EEG recordings can be obtained during the presentation of a
particular stimulus, or in the absence of a stimulus; typically col-
lected with the patient’s eyes closed (i.e. ‘‘resting-state’’ EEG). For
both approaches, the resulting activity can be analysed in various
ways. Event-related activity can be analysed in the time domain
by examining event-related potentials (ERPs); referring to positive
or negative waveforms (i.e. deﬂections in the signal) which occur
following the presentation of a stimulus. For example, the latencyor amplitude of the resulting ERP can be analysed. Alternatively,
frequency bands (where the most commonly-investigated bands
are delta, theta, alpha, beta and gamma) can be examined, in order
to investigate, for example, the observed power within a frequency
band, which can then be compared between patient groups and
healthy control individuals.
Various EEG analytical techniques have been employed in LBD,
such as the use of the Grand Total EEG (GTE) score (a graded com-
posite measure which takes the presence of EEG features such as
diffuse slow-wave activity or focal abnormalities into account),
the analysis of frontal intermittent rhythmic delta activity, and
the use of compressed spectral arrays (Bonanni et al., 2008; Lee
et al., 2015; Roks et al., 2008). A long-standing EEG feature of
DLB is the presence of posterior (temporal) transient slow or sharp
waves (Barber et al., 2000; Briel et al., 1999); the diagnostic criteria
for DLB includes these as a supportive feature of the condition
(McKeith et al., 2005). More recent work has noted that EEG abnor-
malities are typically observed in posterior regions in DLB, whereas
AD patients generally exhibit EEG abnormalities in temporal areas
(Bonanni et al., 2010, 2008), suggesting that topographical EEG
differences are apparent between DLB and AD.
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slow-wave activity relative to healthy controls and individuals
with AD (Bonanni et al., 2008; Briel et al., 1999; Calzetti et al.,
2002; Fernandez-Torre et al., 2007; Roks et al., 2008). Clinically,
this increased slow-wave activity has been found to positively cor-
relate with the presence and severity of cognitive ﬂuctuations
(Bonanni et al., 2008; Walker et al., 2000b). Alterations to EEG
activity also appear to associate with cognition in the LBDs.
Schlede and colleagues investigated an overall measure of EEG
alteration known as the ‘Short Grand Total EEG (GTE)’ score in
LBD, where the Short GTE score was comprised of six separate sub-
scores calculated by visually interpreting certain EEG features (e.g.
diffuse slow activity). The study showed that Short GTE scores,
where higher Short GTE scores indicated more impairment, nega-
tively correlated with a combined MMSE and Clock Drawing Task
(CDT) composite score (Schlede et al., 2011).
One EEG study demonstrated that DLB patients, who were not
taking donepezil, showed increased spectral power density in the
delta and theta bands compared to a control group, which was
not evident in individuals with AD when similarly compared to
the control group (Kai et al., 2005). A greater degree of parietal
delta power band variability has also been reported in patients
with DLB, relative to AD patients and controls (Andersson et al.,
2008). However, increased power in these bands in individuals
with AD has been reported in at least four studies (Jackson and
Snyder, 2008), and thus may represent a non-speciﬁc ‘dementia’
characteristic. Further comparisons between LBD and AD are there-
fore warranted to determine if there is a spectral power density
differential between the two groups, which is sufﬁcient to be use-
ful diagnostically.
Measures of EEG coherence have also been examined, which is a
measure indicative of functional cortical connectivity and in the
context of LBD, a measure which may highlight modulatory effects
of cholinergic deﬁcits (Adler et al., 2003). One such study examined
EEG coherence between four regions (left anterior, right anterior,
left posterior and right posterior) in DLB patients. Compared to
controls, DLB patients showed greater extended coherence (aver-
age coherence between all regions) in the delta band, but reduced
extended coherence in the alpha band (Andersson et al., 2008). In a
similar study, Kai and colleagues also observed differences in DLB
and AD patients in terms of intrahemispheric coherence values,
and differences between DLB and AD in fronto-temporocentral
delta and theta intrahemispheric coherence values, and
temporo-centro-parieto-occipital beta band coherence values; a
result which the authors speculated was due to the greater cholin-
ergic dysfunction in DLB (Kai et al., 2005).
In another study, Caviness and colleagues analysed resting EEG
from PD, PD-MCI and PDD patient groups and observed that the
mean dominant posterior background rhythm frequency (DPBRF)
was signiﬁcantly different between all patient groups (Caviness
et al., 2007). The lowest DPBRF was observed in PDD patients
(7.1 Hz) compared to PD-MCI and PD groups (8.1 Hz and 9.1 Hz
respectively). The groups also differed in terms of delta activity,
where signiﬁcant differences were shown between PDD and
PD-MCI groups. There were also variations in both delta and theta
bands in PDD patients compared to individuals with PD, where
PDD patients showed an increased percentage of global relative
power in both bands. However, as this study did not correct for
multiple comparisons and included a limited number of PDD
patients (n = 8), these results should be interpreted with caution.
The greater temporal resolution afforded by EEG compared to,
for example, neuroimaging methods such as functional blood oxy-
gen level dependent (BOLD) functional magnetic resonance imag-
ing (fMRI), may offer better aetiological perspectives into the
ﬂuctuating perturbations in brain networks that occur in neurode-
generative disease. Certainly in EEG recordings, DLB patients havealso displayed greater ﬂuctuations in frequencies on a
second-by-second basis compared to AD patients and controls,
and these changes in EEG have been causally associated with the
severity and frequency of cognitive ﬂuctuations (Bonanni et al.,
2008; Walker et al., 2000a). Moreover, the frequency variability
in posterior regions also appears to be reduced by the administra-
tion of cholinesterase inhibitors (Kai et al., 2005), suggesting that
EEG parameters could be used as a neurophysiological biomarker
of treatment response. Work conducted in patients with AD has
shown that cholinesterase inhibitors can affect resting-state EEG
activity, where reductions in delta or theta activity have been
observed after successful treatment, accompanied by increases in
dominant alpha activity and cognitive functioning (Babiloni et al.,
2013). It has been suggested that in AD, the use of EEG neurophys-
iological biomarkers might aid the development of new therapeu-
tic treatments, particularly when used alongside other imaging,
biological or cognitive markers (Babiloni et al., 2013) and thus by
extension the use of EEG might also be useful in the LBDs.
One other potential use of EEG which merits further attention is
in the identiﬁcation of individuals in the prodromal phase of the
LBDs, prior to the manifestation of signiﬁcant cognitive impair-
ment. From a theoretical perspective EEG, as a functional marker
of neuronal and synaptic integrity, may be sensitive to subtle and
early neurodegenerative changes that precede overt large-scale
neurodegenerative structural changes in LBD. Empirically, as noted
above, Caviness and colleagues (2007) observed that global delta
activity was intermediate in PD-MCI patients, compared to individ-
uals with PD and PDD. One additional study noted that on the basis
of resting-state EEG recorded from 17 individuals with PD-MCI and
nine with PDD, PDD patients showed signiﬁcantly increased beta
peak frequency, and decreased alpha relative power and alpha/-
theta power, compared to PD-MCI patients at one and two-year
follow-ups (Gu et al., in press). A larger longitudinal study
followed-up 47 individuals with mild cognitive impairment
(MCI), 50 individuals with DLB, 50 with AD and 50 healthy controls
for a period of three years (Bonanni et al., 2015). At the end of the
three-year period, 20 individuals with MCI converted to probable
DLB, and notably, 100% of these individuals displayed EEG abnor-
malities which are typical of DLB at baseline, including a reduced
dominant frequency and increased dominant frequency variability.
Despite the potential limitations of this study, including the focus
on individuals with MCI who were referred to a tertiary centre and
a lack of validation in independent cohorts, these data intriguingly
suggest that EEG might be a useful neurophysiological biomarker
for patients who are on a trajectory towards DLB.
Technical aspects of EEG are likely to impact upon clinical stud-
ies in LBD, and these are likely to be affected by the classic limita-
tion of EEG, which is the ‘inverse problem’, which refers to the
difﬁculties in using spatial EEG measurements to conﬁrm the
actual source of the EEG signal (Koles, 1998). Although various dif-
ferent source localisation methods have been employed to address
this, there is no accepted gold-standard analytical method (Michel
et al., 2004). This potentially limits the utility of EEG, based on the
topographical ﬁndings to date, in addressing aetiological questions
in LBD. Similarly, the ability of the EEG to directly measure deep
cortical and subcortical activity is poor; nevertheless, subcortical
areas and the basal ganglia are likely to be involved in the patho-
physiology of LBD (Peraza et al., 2014). Thus, alternative methods
to EEG are needed to probe these structures and understand their
involvement in LBD symptoms. For example, it would be useful to
conﬁrm whether posterior cortical areas are implicated in the
occurrence of cognitive ﬂuctuations, or alternatively if these symp-
tom phenomena arise frommore diffuse cortical, or indeed subcor-
tical and thalamocortical, neural perturbations.
Several EEG studies with negative ﬁndings have been observed
in the LBDs. In one study, resting EEG recordings obtained from a
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cal diagnoses of AD (n = 45) or DLB (n = 48) were also made retro-
spectively in this study (Londos et al., 2003). The EEG recordings
indicated that theta activity was dominant in both groups with
generalised slow-wave activity, but that there were no signiﬁcant
differences between AD and DLB. However, this study relied on
visual inspection of the EEG rather than objective quantiﬁcation
methods. Whilst subjective approaches to the analysis of EEG data
might provide useful information regarding the underlying patho-
physiology, and determine the presence of DLB or AD compared to
control patients (Liedorp et al., 2009), the major limitation of these
visual inspection approaches is their poor speciﬁcity, despite the
good levels of sensitivity (Brenner et al., 1988; Hooijer et al., 1990).
Advanced semi-automated or fully automated statistical quan-
titative EEG methods, which consider a range of EEG temporal
and spatial features, have allowed for marked improvements in
speciﬁcity in separating DLB from AD (Bonanni et al., 2010, 2015,
2008; Snaedal et al., 2012). Such approaches have included the
application of compressed spectral arrays (Bonanni et al., 2010,
2015, 2008), a technique developed for EEG monitoring during
coma (Karnaze et al., 1982), which can be easily used in a clinical
environment and displays the power expressed by frequency
bands every two seconds. This provides a rapid on-line approach
to assessing EEG frequency variability, which is a key feature in
LBD. Others have applied statistical pattern recognition algorithms
in order to discriminate between different dementia subtypes
(Engedal et al., 2015; Snaedal et al., 2012). Overall, whilst these
techniques are promising, their widespread translation to clinical
practice has not yet occurred and these approaches need to be
replicated and validated outside of their respective research
centres.
4.2. Event related potential studies
When a particular stimulus (e.g. auditory or visual) is presented
to an individual with concurrent EEG monitoring, event-related
potentials (ERPs) can be observed in the subsequent time-locked
EEG activity. ERPs are deﬁned in accordance with the polarity,
referring to whether the resulting waveform is positive or negative,
and in terms of the latency following the stimulus presentation,
which is measured in milliseconds (ms). For example, the ‘P300’
ERP represents a positive waveform, observed 300 ms following
the presentation of a stimulus (Luck, 2005). ERP studies thus might
offer a method by which attentional or other cognitive deﬁcits in
LBD can be accurately characterised.
Although the current literature on ERPs in LBD patients is rela-
tively sparse (see Supplementary Table S1), several studies have
demonstrated that atypical ERPs are a common feature of LBD
(Bonanni et al., 2010; Kurita et al., 2010; Perriol et al., 2005;
Pugnetti et al., 2010). Whilst the use of ERPs in the LBDs may have
important implications for understanding pathophysiology; for
example, by providing a better understanding of attentional dys-
function or visual hallucinations (Brønnick et al., 2010; Kurita
et al., 2010), there is less evidence to suggest that they are useful
from a diagnostic perspective, as generally, these studies do not
report sensitivities and speciﬁcities.
One study conducted by Bonanni and colleagues, using an audi-
tory ‘oddball’ paradigm, showed that the P300 was lower in ampli-
tude and had a greater latency in DLB patients compared to AD
patients (Bonanni et al., 2010), and the pattern of P300 amplitude
gradients was inverted (i.e. there was a higher amplitude in frontal
leads and smaller amplitude in posterior leads in DLB patients
compared to AD and controls). This may appear counterintuitive,
as reduced amplitudes might be expected in LBD, which is charac-
terised by early frontal lobe involvement with the co-occurrence of
dysexecutive symptoms (Dodel et al., 2008). Nevertheless, delayedP300 latencies were evident in DLB patients studied in anterior,
rather than posterior, regions compared to AD, which is compatible
with the cognitive phenotype common to LBD. Furthermore, the
delayed P300 response in DLB correlates with the severity of cog-
nitive ﬂuctuations, thus suggesting that the P300 latency may also
serve as a useful objective neurophysiological biomarker for the
severity of this core symptom (Bonanni et al., 2010). From a clinical
perspective, the presence of a reversed amplitude distribution, in
those with a reliable P300 response, differentiated DLB from AD
patients with a sensitivity of 70% and speciﬁcity of 97% (Bonanni
et al., 2010).
Other approaches have included the use of the prepulse inhibi-
tion (PPI) paradigms in conjunction with simultaneous EEG record-
ing; to date, only one study has employed this method in patients
with LBD (Perriol et al., 2005). The PPI paradigm involves the pre-
sentation of a weak auditory stimulus immediately prior to the
presentation of a stronger stimulus, resulting in a ‘startle response’.
Typically, in healthy individuals the second pulse is perceived as
irrelevant and is ﬁltered out, which is reﬂected in suppression of
the ERP waveform (Oranje et al., 2006). Perriol and colleagues
investigated attentional selectivity using the PPI paradigm in AD,
DLB, PDD and healthy control individuals, where an 80 decibel
(dB) sound pulse preceded a 115 dB sound pulse (Perriol et al.,
2005). The percent PPI of the N100/P200 component amplitude
was signiﬁcantly reduced in the DLB group relative to AD patients
and controls, whilst the PDD group exhibited intermediate PPI dis-
turbances, where the percentage of PPI was signiﬁcantly reduced
compared to controls. The authors speculated that the reduced
PPI reﬂects a more severe disruption of the dopaminergic
subcortico-thalamo-cortical networks in DLB compared to PDD
(Perriol et al., 2005).
From the limited work thus far, it is evident that ERP studies
may help make signiﬁcant inroads into understanding clinical
symptoms and cognitive dysfunction in LBD, as well as potentially
providing ways to differentiate LBD from other dementias.
However, aside from technical issues such as the inverse problem,
other challenges remain. Due to the nature of ERP-associated tasks,
it is necessary that an individual has the ability to sustain their
attention to task stimuli over a large number of trials in order to
generate an adequate signal-to-noise ratio. Effectively completing
a paradigm may be particularly difﬁcult for LBD patients who have
signiﬁcant cognitive impairment and/or who experience ﬂuctua-
tions in attention.
4.3. Magnetoencephalography
Magnetoencephalography (MEG) provides another ‘window’
into the brain and involves the detection of the electromagnetic
ﬁeld generated by postsynaptic currents in cortical pyramidal neu-
rons (Hari and Salmelin, 2012). Compared to EEG, because the
magnetic ﬁeld is not attenuated by the skull or scalp, MEG can
be used to acquire very high-frequency activity which cannot be
captured using EEG (Hari et al., 2010). MEG is sensitive to cortical
currents which are tangential to the skull and in cortical ﬁssure
walls, whereas EEG detects currents in all orientations (Hari
et al., 2010; Hari and Salmelin, 2012). Importantly, MEG does not
require a reference source (i.e. where the signal is compared to a
signal measured from a separate location) and can also measure
neural activity without requiring physical contact with the skull,
which can increase the speed of application (Hämäläinen et al.,
1993; Hari et al., 2010).
Two resting-state MEG studies have reported abnormal cortical
rhythms in LBD patients with evidence of cortical rhythm slowing,
particularly in posterior regions, consistent with EEG data
(Bosboom et al., 2009; Franciotti et al., 2006). In the ﬁrst study,
Franciotti and colleagues analysed a range of frequency bands in
354 R.A. Cromarty et al. / Clinical Neurophysiology 127 (2016) 349–359a small number of moderate and severe AD and LBD patients, and
control individuals, during conditions in which participants had
their eyes closed or eyes open. EEG recordings were also obtained
during a simple mental arithmetic task. The measurement of alpha
and pre-alpha cortical reactivity, during both open and eyes-closed
conditions, was able to differentiate control participants from
patients, and also separated individuals with moderate AD from
those with severe AD and LBD (Franciotti et al., 2006). However,
it is unclear if this study indicates that the underlying activity
observed in patients with severe AD is similar to the underlying
activity in DLB.
In the second study, Bosboom and colleagues conducted a
resting-state MEG study during which they treated a small sample
of eight PDD patients with the cholinesterase inhibitor rivastig-
mine (Bosboom et al., 2009). The treatment was found to reverse
some of the slowing of resting-state activity (resulting in a shift
in the frequency spectrum towards higher frequencies), providing
further support for the notion of cholinergic system dysregulation
in PDD. Interestingly, greater levels of post-treatment cognitive
improvements were positively associated with a smaller reduction
in relative delta power, suggesting that a better clinical response
was associated with lower baseline levels of delta power. A nega-
tive association was also found between cognitive improvements
and relative theta power changes. These data potentially indicate
that the mechanism by which rivastigmine exerts therapeutic
effects in LBD patients, particularly the amelioration of cognitive
deﬁcits (Maclean et al., 2001), could be due to the normalisation
of the cortical rhythms (i.e. a shift towards higher frequencies).
Speculatively, cortical rhythms observed during resting-state
MEG, and post-treatment changes in the frequency of
resting-state cortical rhythms, might be effective neurophysiolog-
ical biomarkers of cholinesterase inhibitor (or other agents) treat-
ment efﬁcacy in LBD. However, no further MEG studies have been
conducted to date in order to validate this. From a clinical perspec-
tive, the use of MEG in the diagnosis and monitoring of LBD is,
however, likely to be limited given the relative expense of MEG
facilities and lack of availability, as they are often located only in
major research centres.4.4. Blink reﬂex studies
The blink reﬂex is typically used to assess lesions to the brain-
stem and involves the measurement of the reaction to electrical
stimulation of the supraorbital nerve, from which the latency to
three separate responses can be derived (Bonanni et al., 2007).
The ﬁrst response, R1, is generated in the trigemino-facial reﬂex
arc, and R2 and R3 are generated in polysynaptic pathways involv-
ing the brainstem reticular formation (Bonanni et al., 2007).
Bonanni and colleagues hypothesised that as brainstem neu-
ropathology has been proposed to be a feature of early LBDs
(Braak et al., 2003), the blink reﬂex might be abnormal in DLB
and particularly in patients with rapid eye movement sleep beha-
viour disorder (RBD) (Bonanni et al., 2007). In their study, healthy
controls and patients with DLB, multiple system atrophy (MSA),
progressive supranuclear palsy, and AD were assessed. The DLB
group showed a signiﬁcantly delayed blink reﬂex response
(increased R2 latency) relative to all other groups (Bonanni et al.,
2007). These results were independent of the presence or absence
of RBD, as delayed R2 latencies were observed in ﬁve DLB patients
who did not display RBD, suggesting that R2 latencies are not a
marker of brainstem neuropathology. Whilst the R2 latency might
be a useful diagnostic biomarker, to date, no other blink reﬂex
studies have been carried out in order to conﬁrmwhether this neu-
rophysiological marker is sufﬁciently robust to diagnostically sep-
arate DLB from other patient groups.From a treatment response perspective, the blink reﬂex may
have utility as a biomarker; Anzellotti and colleagues investigated
the effect of the cholinesterase inhibitor donepezil upon the blink
reﬂex response in 26 DLB patients and 20 AD patients (Anzellotti
et al., 2008). Blink reﬂexes were assessed at a baseline period
and following treatment with donepezil. In the DLB group, the R2
latency of the blink reﬂex was signiﬁcantly reduced by 8.2% rela-
tive to baseline and was accompanied by a post-treatment reduc-
tion in cognitive ﬂuctuations. However, the blink reﬂex response
does suffer from some limitations which may inhibit its clinical
use; ﬁrstly, blink reﬂex recording is technically difﬁcult, as the
electrical pulse delivered to the supraorbital trigeminal nerve
branch can spread and distort the subsequent measurement and
secondly, the stimulus can be unpleasant or moderately painful.
4.5. Other techniques
Aside from the methodologies mentioned above, a variety of
other neurophysiological techniques have been employed in order
to investigate LBD. Koﬂer and colleagues investigated the auditory
startle reaction (ASR) in patients with DLB compared to patients
with other Parkinsonian disorders and healthy control individuals
(Koﬂer et al., 2001). The ASR paradigm in this study involved pre-
senting participants, who reclined on a bed in a quiet
semi-darkened room, with auditory tone bursts of a random fre-
quency and intensity. The subsequent effects upon EMG measure-
ments, obtained from a range of areas (orbicularis oculi, masseter,
sternocleidomastoid, biceps brachii, abductor pollicis brevis, rectus
femoris, tibialis anterior, and soleus muscles), were then examined.
DLB patients showed an abnormal ASR proﬁle, displaying fewer
ASRs than healthy control individuals and virtually no responses
in lower extremities. The probability of ASRs was similar in facial
areas, the neck and in the upper extremities when DLB patients
were compared to patients with PD or with MSA, although the
amplitude of ASRs were markedly lower in DLB patients compared
to PD patients and control individuals, which the authors specu-
lated may have been as a result of brainstem pathology occurring
in DLB (Koﬂer et al., 2001).
Alternative physiological biomarkers might include the exami-
nation of autonomic abnormalities. Negami and colleagues exam-
ined the sympathetic skin response (SSR) and heart rate
variability (HRV) in a comparison of patients with AD (n = 20) with
a group of DLB patients (n = 20) (Negami et al., 2013). The SSR,
which reﬂects the sympathetic sweat response and which was
measured by the response to induced median nerve stimulation,
was shown to be lower in individuals with DLB compared to AD.
Additionally, the ratio of low-frequency to high-frequency power
in HRV was signiﬁcantly lower in DLB patients compared to AD.
Based on the cut-off values employed in this study, the sensitivities
of the SSR and HRV were 85% and 90% respectively, and the speci-
ﬁcity of each technique was 85% and 85%. Similarly, Akaogi and
colleagues also observed autonomic differences in DLB and PDD
patients relative to PD patients and controls (Akaogi et al., 2009).
In this study, the sympathetic sweat response and skin vasomotor
reﬂex were measured from the palm of the hand. Cardiovascular
function was also assessed, expressed as the coefﬁcient of variation
of R-R intervals (CVR–R) measured in response to the head-up tilt
test. The LBD and PD patients displayed reduced sweat response
amplitudes compared to controls, and the vasomotor reﬂex ampli-
tudes were also lower in LBD, but not PD patients, compared to
controls. In addition, DLB patients showed a signiﬁcantly lower
CVR–R value (Akaogi et al., 2009).
Overall these ﬁndings suggest that autonomic biomarkers merit
further investigation in LBDs. They may also be particularly salient
to the detection of early disease (i.e. prodromal DLB) given the
expectation that autonomic symptoms may predate the
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Lewy body disease by a number of years (Donaghy et al., 2015).
4.6. Transcranial magnetic stimulation
Transcranial magnetic stimulation (TMS) is a non-invasive cor-
tical stimulation technique which has been used in LBD in order to
evaluate excitatory/inhibitory characteristics of the cortex, and in
particular, the corticomotor system. Examples of TMS approaches
include short intra-cortical inhibition (SICI; Figs. 2A and C),
intra-cortical facilitation (ICF; Figs. 2B and C) and short-latency
afferent inhibition (SAI; Fig. 3A).
To date, the application of these cortico-motor parameters to
LBD cohorts has been limited. Two studies have examined SICI, a
cortico-motor based measure which is a possible surrogate for
GABAergic function (Stagg et al., 2011), in DLB (Di Lazzaro et al.,
2007; Nardone et al., 2006); however, in the study conducted by
Di Lazzaro and colleagues, no signiﬁcant differences were observed
in SICI between DLB, AD and controls (Di Lazzaro et al., 2007).
Similarly, Nardone and colleagues reported no signiﬁcant differ-
ences in SICI in DLB patients compared to controls, although reduc-
tions were shown in AD patients (Nardone et al., 2006). Work in PD
cohorts has suggested that alterations to cortical silent periods
(cSPs) and ipsilateral silent periods (iSPs) might be a feature of
PD (Morita et al., 2008), but it is not known whether changes in
these cortico-motor parameters extend into the LBDs. Other TMS
methodologies include the measurement of motor evoked poten-
tial (MEP) thresholds, long-interval intracortical inhibition (LICI)
(Cantone et al., 2014) and ‘paired-pulse’ protocols, which canFig. 2. Short-interval intracortical inhibition (SICI) and intracortical facilitation (ICF).
unconditioned MEPs from a 50 year old healthy control participant at rest (i.e. no backgro
conditioning pulses were delivered at 80% resting motor threshold (RMT) and test pu
conditioned MEPs are plotted either in red (3 ms interstimulus interval; SICI), or green (1
MEPs. (C) Comparison of mean SICI and ICF in healthy control participant. Each data poin
MEP. Error bars represent standard error. In the age-matched control MEPs are signiﬁ
p < 0.05). (For interpretation of the references to color in this ﬁgure legend, the reader imeasure cortical interhemispheric inhibition and transcallosal
function (Ferbert et al., 1992). However, studies are yet to examine
these measures in LBD.
One cortico-motor TMS parameter which has been applied
more extensively in DLB cohorts is that of short-latency afferent
inhibition (Fig. 3) (Celebi et al., 2012; Marra et al., 2012; Nardone
et al., 2006). This measure has been mooted to be an in vivo bio-
marker of cholinergic function and has been reported to be reduced
in dementias which have signiﬁcant neuropathologic evidence of
cholinergic loss. Therefore, for example, SAI alterations are not
observed in fronto-temporal dementia (Di Lazzaro et al., 2006)
but DLB patients show a reduced SAI compared to healthy controls
(Di Lazzaro et al., 2007; Marra et al., 2012). However, the SAI liter-
ature is not consistent in DLB; for example, Nardone and colleagues
did not observe any SAI or SICI differences between DLB patients
and controls (Nardone et al., 2006).
From a PDD perspective, despite numerous reports on SAI in PD
(Nardone et al., 2005; Rochester et al., 2012; Sailer et al., 2003;
Yarnall et al., 2013), only one preliminary report has demonstrated
that SAI is reduced in PDD compared with PD (Celebi et al., 2012).
Compared to cognitively normal patients with PD and healthy con-
trols, individuals with PD-MCI have been shown to have a signiﬁ-
cantly reduced SAI, indicating that SAI could be a useful
neurophysiological biomarker of cholinergic dysfunction, even in
the earliest stages of cognitive decline (Yarnall et al., 2013).
However, comparable data in DLB are currently lacking.
SAI, as an indirect in vivomeasure of cholinergic function, might
also serve as a means of understanding symptom aetiology in LBD;
a small number of reports have examined the relationship between(A) Figure showing the experimental procedure for SICI/ICF. (B) Conditioned and
und EMG contraction). To measure both SICI and intracortical facilitation (ICF) TMS
lses were delivered at 120% RMT. Unconditioned MEPs are plotted in black and
0 ms interstimulus interval; ICF). Each trace is an average of 20 individual rectiﬁed
t is an average of 20 MEPs. Test MEPs are normalised to the unconditioned (control)
cantly affected by short interval and long interval conditioning (two-tailed t test;
s referred to the web version of this article.)
Fig. 3. Short-latency afferent inhibition (SAI). (A) Experimental procedure for SAI. (B) Examples of conditioned and unconditioned motor evoked potentials (MEPs) produced
by a short-latency afferent inhibition (SAI) protocol in a 66-year-old control participant. Time intervals between the conditioning median nerve stimulation (set 20% above
threshold for observing a twitch in abductor pollicis brevis) and the TMS test pulse (set at 1.2 times resting motor threshold) are expressed relative to the latency of the N20
component of the somatosensory evoked potential (SEP) measured in each individual (e.g. N20+2 ms). Averaged unrectiﬁed MEPs have been plotted (each trace represents an
average of 20 individual sweeps). Time voltage calibration bars apply to all MEPs, but note the colour coding for voltage calibration).
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One study found that SAI was reduced in non-demented PD
patients with visual hallucinations compared to those without,
and that these changes were accompanied by selective deﬁcits in
attentional and visuospatial function (Manganelli et al., 2009).
Therefore, a reduction in SAI, in the presence of visual hallucina-
tions and subtle cognitive impairment, may be related to choliner-
gic dysfunction in PD patients at a higher risk of progressing to
dementia. Related to this, SAI also appears to correlate with visual
hallucination severity in DLB, further supporting the argument that
cholinergic deﬁcits are apposite to the aetiology of this core symp-
tom (Marra et al., 2012). However, relevant factors including dis-
ease heterogeneity, small sample sizes, and concurrent
psychotropic medication use, which is known to inﬂuence the
effects of TMS (Ziemann, 2004), might limit the clinical utility of
SAI as a neurophysiological biomarker in the LBDs, as these factors
have undoubtedly contributed to the variable SAI ﬁndings
observed in LBD (Di Lazzaro et al., 2005; Nardone et al., 2005).
Outside of the corticomotor system, TMS has been applied to
the visual cortex to help address the aetiology of visual hallucina-
tions in DLB. Phosphene thresholds, which provide a marker of cor-
tico visual excitability, were evaluated in DLB patients compared to
controls in a study by Taylor and colleagues (Taylor et al., 2011).
This study showed that phosphene thresholds and their associated
parameters were not signiﬁcantly different between groups, but
there was a positive correlation between visual cortical hyperex-
citability and the severity and frequency of visual hallucinations.
The authors therefore suggested that whilst increases in visual cor-
tical excitability do not explain visual hallucinations, TMS visual
excitability might be a neurophysiological biomarker of symptom
frequency and severity. Whilst TMS is undoubtedly a promising
research technique, it may be unsuitable for routine clinical use
due to the time-consuming and technical nature of TMS protocol
delivery.5. Conclusions
It is evident that a wide range of neurophysiological approaches
can potentially be used as useful LBD biomarkers. Potential uses
include: the accurate and reliable identiﬁcation of individuals with
LBD compared to other dementias or healthy individuals; as objec-
tive markers of cognitive or neuropsychiatric symptom severity, or,
as a marker of treatment response.
However, there are a series of limitations inherent in the studies
conducted to date. Firstly, of the studies which have examined
neurophysiological biomarkers in the LBDs comparing patient
groups, sample sizes have been relatively small (e.g.; Briel et al.,
1999; Calzetti et al., 2002; Kai et al., 2005; Schlede et al., 2011).
In addition to the small sample size issue, even when patients
included in the studies have met the relevant diagnostic criteria
for DLB and PDD, there has been a great deal of heterogeneity in
the patient cohorts. This is particularly apparent with regard to
the disease severity and underlying disease pathology.
The use of medication in the studies reported to date is also a
potential limitation. Cholinesterase inhibitors are generally used
in patients with DLB, and levodopa medications are generally used
in patients with signiﬁcant parkinsonian symptoms; however, lit-
tle is known regarding the effects of these medications, or combi-
nations thereof, upon the range of neurophysiological biomarkers
discussed in the present review. The evidence from the studies
included in the review is mixed, as whilst the use of medication
(anti-depressants, benzodiazepines and neuroleptics) was not
shown to affect measures of EEG coherence in one study
(Andersson et al., 2008), the administration of donepezil was
shown to affect delta and theta band mean power in another EEG
study (Kai et al., 2005).
Another limitation is that the replication of previous studies, in
larger cohorts, is lacking. Such studies are necessary in order to
accurately assess the diagnostic utility of the neurophysiological
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of speciﬁcity and sensitivity when using neurophysiological mark-
ers to compare between clinical groups of patients, and where
cut-off values have been used to separate groups of individuals
with different types of dementia, it has generally been the case that
the cut-off values employed have not been speciﬁed in advance
(e.g. Andersson et al., 2008). These challenges undermine the pos-
sibility of carrying out robust meta-analytic testing of neurophys-
iological biomarkers in LBD.
In order to overcome these clear methodological limitations and
increase the utility of neurophysiological biomarkers, we recom-
mend the following, as a research priority:
(1) Replicative studies, with large numbers of patients, are
needed. This will allow the accurate assessment of the valid-
ity and reliability of neurophysiological markers and enable
meta-analyses to be conducted.
(2) The effects of common pharmacological agents used as
treatment in the LBDs upon neurophysiological biomarkers
should be examined and reported in studies. This is neces-
sary as it is possible that the use of common treatments such
as cholinesterase inhibitors, psychotropics (e.g. antipsy-
chotics, benzodiazepines, etc.) or anti-parkinsonian medica-
tions, might differentially affect EEG, MEG or TMS measures
in particular. Subsequently, this is likely to impact upon the
utility of the neurophysiological marker, as either a diagnos-
tic tool, or as a marker of treatment efﬁcacy.
(3) Efforts should be focussed on developing the efﬁcacy of EEG
as a diagnostic tool in LBD. Pragmatically, EEG is a relatively
inexpensive technique, and the development of new
methodologies and automated analysis techniques now
mean that EEG can have greater diagnostic speciﬁcity com-
pared to subjective visual or manual approaches (Bonanni
et al., 2010; Snaedal et al., 2012). However, a standardised
analytical approach to EEG, which can be applied in clinical
situations, is still needed for EEG to be an effective neuro-
physiological diagnostic biomarker in LBD.
(4) Neurophysiological biomarkers are not usually examined in
isolation, and combinative approaches with other biomark-
ers (neurophysiological or otherwise) might improve sensi-
tivity and speciﬁcity (Shaw et al., 2007). For example, Hari
and colleagues note that the combined use of MEG, EEG
and structural and functional magnetic resonance imaging
recordings provide the most information regarding brain
function (Hari et al., 2010). In this context, for example,
studies which could combine SAI or EEG with neuroimaging
may improve their diagnostic utility, by examining both
structural and functional divergences, and phenotypic varia-
tions between diseases such as DLB and AD.
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